<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125962">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01773174</url>
  </required_header>
  <id_info>
    <org_study_id>1160.145</org_study_id>
    <nct_id>NCT01773174</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to &lt; 2 Years of Age</brief_title>
  <official_title>Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study will assess PK/PD parameters and safety and tolerability of the study medication in
      this age group
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ecarin clotting time (ECT)</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor IIa inhibition</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all bleeding events</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all adverse events</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of total dabigatran</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of free dabigatran</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of BIBR 1048 BS (Base)</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of BIBR 951 BS</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of BIBR 1087 SE (Acid)</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Activated prothrombin time (aPTT)</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability will be summarized across all patients in the treated set</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of taste will be summarized across all patients in the treated set</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory and clinical parameters</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose treatment with dabigatran oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>age &amp; weight adjusted equivalent of adult dose</description>
    <arm_group_label>dabigatran etexilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. males or females 1 to less than 2 years of age

          2. objective diagnosis of primary venous thromboembolism

          3. completion of planned treatment course with low molecular weight heparin or oral
             anticoagulant for primary venous thromboembolism

          4. written informed consent by parent (legal guardian) and patient assent (if
             applicable)

        Exclusion criteria:

          1. weight less than 10 kg

          2. conditions associated with increased risk of bleeding

          3. patients who have any condition that would not allow safe participation in study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1160.145.00007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.145.0006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1160.145.00001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
